Who’s in London Nov. 16-19th? Let’s meet up!
Psilera comes to #London in two weeks!
The team will meet with key investors and leaders in the European #neuropsychiatry community ahead of the 2027 #clinicaltrial for PSIL-006
Email [email protected] to reserve your time
#Neuroplastogens #CNS #Innovation
5-MeO-DMT showing big promise in depression trials. Phase 3 trial in progress and just acquired by @EliLillyandCo for $2.8B+.
A fast-acting nasal spray offers hope for hard-to-treat depression: study trib.al/asateiX
Building out a world-class clinical team @psilera for our next-generation #neuroplastogens. Welcome aboard (formally) Allyson!!
Psilera prepares for the clinical advancement of its lead #neuroplastogen #PSIL-006 by appointing a VP of #ClinicalDevelopment.
Read the press release for full details:
prn.to/3UCxhpV
LFG!!! 🇺🇸
Folarin Balogun will be available to play the USMNT’s round of 16 match against Belgium, with his one-game red-card ban that he received against Bosnia and Herzegovina suspended.
Article 27 of FIFA’s disciplinary code states that “the judicial body may decide to fully or partially suspend the implementation of a disciplinary measure.”
nyti.ms/3RkeoH5
We’ve made carbon to carbon bonds at the 4-position of tryptamines for the first time. So much #neuroplastogen chemical white space that we’re tapping into @psilera.
Psilera Debuts Novel Synthetic Platform to Aid Discovery of #Neuroplastogens in New #Publication
The peer-reviewed research identifies #4BrDMT as a synthetic building block to expand and diversify our #neuroplastogen #DrugDiscovery capabilities.
prnewswire.com/news-releases…
In Miami today -> tomorrow. Let’s meet on the beach and talk #neuroplastogens and #psychedelics!
#Oppenheimer's #CNS and #NeuroMuscular Summit in #Miami is today!
A highlight of the day's agenda will be a panel featuring Chris Witowski, PhD, and industry KOLs discussing the industry and solutions for the future.
#Innovation #Neuroplastogens #Psychedelics #DrugDiscovery
Proud to announce the formal close of Psilera’s seed round bringing our total funds raised to $9M. Couple this with our revenue generating deal (with additional upside) and #NIH funding it has been quite a year and change for us!
Psilera has closed an oversubscribed $8.8M raised #SeriesSeed funding round!
#FirstInClass and #FirstInHuman data expected in 2027.
Read the full details in the press release below: prnewswire.com/news-releases…
#MindfulMedicine #Psychedelics #Neuroplastogens
Even more important is this financing readies us for clinical trials with PSIL-006 next year. We are well-positioned with an industry-leading patent portfolio and a differentiated #neuroplastogen pipeline. Stay tuned for some big milestones over the next 12 months!
Anyone in SD for Bio next month?
One month until #BIOConvention: where #biotech & #biopharma meet for #partnering and #innovation.
The team will be in #SanDiego sharing the latest #data from Psilera's #nextgeneration #psychedelic and #neuroplastogen pipeline.
Email [email protected] to schedule a meeting.
Will be a great time in Miami with @Oppenheimer and other CNS leaders. We’re reaching a pivotal inflection in the #psychedelics and related #neuroplastogens.
Look forward to discussing these developments and the latest progress at @psilera.
Co-Founder and CEO Chris Witowski, PhD, is a featured panelist at #Oppenheimer's #CNS Focus Event in #Miami 6/10/26
To meet with him and learn the latest about our #neuroplastogen pipeline, email us at [email protected]
#Innovation #Psychedelics #DrugDiscovery #MindfulMedicine
Get ready, multiple #psychedelic drug approvals are coming. New options for patients, who often don’t respond to current treatments, is a great thing for depression and PTSD (~35 million in the US alone).
Following President Trump’s directive to accelerate medical treatments for serious mental illnesses, FDA announced major steps to support the development of serotonin-2A agonists & related products—a class of medications historically referred to as "psychedelic" drugs.
✅ National priority vouchers for psilocybin (for treatment-resistant depression and major depressive disorder)
✅ National priority voucher for methylone (for post-traumatic stress disorder)
✅ First-ever noribogaine study authorized for alcohol use disorder
✅ Advancing guidance for sponsors developing these products
Learn more: fda.gov/news-events/press-an…
A big headline this weekend with the signing of the Executive Order on #psychedelics.
Replying to @psilera
@Psilera is bolstered by the #ExecutiveOrder signed in support of advancing #psychedelictherapies to help patients in need!
prnewswire.com/news-releases…
#Psychedelics #Psilocybin #Neuroplastogens #DrugInnovation #DrugDevelopment #MindfulMedicine
Love this. The thing that’s never squared with me on autonomous vehicles is that it’s still 1 car 1 person. Traffic and time are still the same. Look at rail in Europe/abroad people use it hundreds of years later for a fraction of a car.
Even better idea: connect this rail to downtown St. Pete. Can be done <30 min even in rush hour. Once in a generation opportunity that benefits all of Tampa Bay. This is the way.
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
This is the beginning of the end for Trump, mark this tweet.
President Trump Delivers an Address to the Nation, Apr. 1, 2026 xitter.gq/i/broadcasts/1yKAPMqQd…






















